The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Sep. 27, 2016

Filed:

Dec. 14, 2012
Applicants:

Board of Regents, the University of Texas System, Austin, TX (US);

Dana-farber Cancer Institute, Inc., Boston, MA (US);

Inventors:

Florian L. Muller, Houston, TX (US);

Eliot Fletcher-Sananikone, Houston, TX (US);

Simona Colla, Houston, TX (US);

Elisa Aquilanti, Boston, MA (US);

Ronald DePinho, Houston, TX (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 48/00 (2006.01); C07H 21/02 (2006.01); C07H 21/04 (2006.01); A61K 31/713 (2006.01); A61K 45/06 (2006.01); A61K 31/191 (2006.01); A61K 31/5685 (2006.01); A61K 31/662 (2006.01); A61K 31/198 (2006.01); A61K 31/35 (2006.01); A61K 31/352 (2006.01); A61K 31/357 (2006.01); G01N 33/50 (2006.01); G01N 33/574 (2006.01); C12Q 1/68 (2006.01); A61K 31/661 (2006.01); C12N 15/113 (2010.01);
U.S. Cl.
CPC ...
A61K 31/713 (2013.01); A61K 31/191 (2013.01); A61K 31/198 (2013.01); A61K 31/35 (2013.01); A61K 31/352 (2013.01); A61K 31/357 (2013.01); A61K 31/5685 (2013.01); A61K 31/661 (2013.01); A61K 31/662 (2013.01); A61K 45/06 (2013.01); C12N 15/1137 (2013.01); C12Q 1/6886 (2013.01); G01N 33/5038 (2013.01); G01N 33/5743 (2013.01); G01N 33/57407 (2013.01); A61K 48/00 (2013.01); C12N 2310/14 (2013.01); C12N 2310/531 (2013.01); C12N 2320/31 (2013.01); C12Q 2600/106 (2013.01); C12Q 2600/156 (2013.01); C12Y 402/01001 (2013.01); C12Y 402/01011 (2013.01); G01N 2333/988 (2013.01); G01N 2800/52 (2013.01);
Abstract

Methods for treating a subject determined to have a cancer comprising a heterozygous inactivation of a housekeeping gene (or a homozygous deletion of a functionally redundant housekeeping gene) by treating the subject with an inhibitor of the gene. For example, a subject having a cancer with an ENO gene deletion can be treated with a glycolysis inhibitor, such as an enolase inhibitor. In some aspects, a subject having a cancer with an ARS gene deletion can be treated with an ARS inhibitor.


Find Patent Forward Citations

Loading…